Tranexamic acid significantly reduces blood loss and transfusion needs during cancer surgeries, which can improve patient outcomes.

• In 16 trials with 1,830 patients, TXA cut total, intraoperative, and postoperative blood loss compared to control.
• It lowered intraoperative blood component need and perioperative red blood cell transfusions.

TXA may also modestly reduce operative time without increasing complications or mortality.

• Certainty of evidence varied, with many outcomes rated moderate or low quality.